Antibody antagonists of ve-cadherin without adverse effects on vascular permeability

a technology of vecadherin and anti-vecadherin, which is applied in the field of anti-vecadherin anti-antagonizers without adverse effects on vascular permeability, can solve the problems of vascular leak syndrome, hemorrhage and death, and disturbance of normal vasculature integrity

Inactive Publication Date: 2008-12-18
IMCLONE SYSTEMS
View PDF12 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0022]Yet another embodiment of the invention provides a method for reducing or inhibiting tumor vasculature in a mammal by administering a pharmaceutical composition of the invention to a mammal in an amount effective to inhibit blood vessel formation without adversely affecting existing vasculature, i.e., so to eliminate or substantially reduce or restrict blood flow to a tumor without adversely affecting existing vasculature.
[0024]In yet a still further embodiment the present invention is directed to a method of gene therapy to deliver the antibody or antibody fragment of the invention to a mammalian host. This method is comprises administering a nucleic acid encoding the desired antibody or antibody fragment to a mammal in an amount and for a time effective to inhibit angiogenesis at a predetermined site or to inhibit tumor neovascularization.

Problems solved by technology

For example, administering certain anti-cadherin antibodies in amounts sufficient to prevent or inhibit angiogenesis have resulted in disturbances in the integrity of normal vasculature with resultant vascular leak syndromes, hemorrhage and death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody antagonists of ve-cadherin without adverse effects on vascular permeability
  • Antibody antagonists of ve-cadherin without adverse effects on vascular permeability
  • Antibody antagonists of ve-cadherin without adverse effects on vascular permeability

Examples

Experimental program
Comparison scheme
Effect test

example 1

Methods

[0078]Monoclonal Antibody Preparation: Lewis rats (6-8 week old females) were injected subcutaneously (s.c.) with 0.1 ml of protein or peptide mixed in Freund's complete adjuvant using a 25-gauge needle. Rats were boosted every 2-3 weeks with antigen and bled via the tail vein every week. After 3 booster immunizations or when sera titers reach maximal levels, mice were sacrificed by CO2 inhalation. Spleens were recovered from sacrificed animals for monoclonal antibody generation by conventional techniques.

[0079]Antibody Screening: Hybridoma supernatants were screened in by an enzyme-linked immunosorbent assay (ELISA) to identify antibodies which bound to VE-cadherin.

[0080]Junction Formation / Ca Switch Assay: The junction formation assay was developed based on a modification of the calcium switch assay (Gumbiner, B., & Simons, K., Cell Biol. 102:457-468 (1986)). Transfectant CHO cells or endothelial cells expressing VE-cadherin are plated onto glass slides and allowed to form a...

example 2

VE-Cadherin Monoclonal Antibodies That Inhibit Adherens Junction Formation Without Disrupting Existing Junctions

[0084]Two groups of Lewis rats were immunized with either a mixture of four KLH-coupled peptides having sequences from the N-terminal domain 1 of murine VE-cadherin (FIG. 2) or with affinity-purified soluble mouse VE-cadherin (smVEC-Ig) which had been expressed in CHO cells. This immunogen encompasses the entire extracellular region of mouse VE-cadherin fused to human Fc chain. The resulting hybridoma clones were tested for production of antibodies with binding activity to VE-cadherin using a conventional ELISA format. This screening identified twenty (20) rat anti-murine VE-cadherin antibodies, 10 from each of the originally immunized groups of rats.

[0085]Several properties of these monoclonal antibodies were examined and the results are summarized in Tables 1 and 2.

[0086]The 20 candidate VE-cadherin antibodies were tested in the “calcium-switch” and “permeability” assays...

example 3

E4B9 Cross Reacts with Human VE-Cadherin

[0087]The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cell indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
sizeaaaaaaaaaa
paracellular permeabilityaaaaaaaaaa
Login to view more

Abstract

The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin. (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a divisional application of U.S. patent application Ser. No. 10 / 040,128 filed Jan. 2, 2002, which is a continuation of U.S. application Ser. No. 09 / 540,967 filed Mar. 31, 2000, now abandoned, the contents of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to antibody antagonists of VE-cadherin that inhibit formation new of adherens junctions without disrupting the integrity of existing junctions. Such antibodies are useful to prevent angiogenesis in a variety of disease conditions, including, for example, to prevent neovascularization of tumors. These antibodies are also useful for treating endothelial cell proliferative disorders.BACKGROUND OF THE INVENTION[0003]Many diseases are associated with an abnormal proliferation of blood vessels. The process of forming new blood vessels is termed angiogenesis. Under normal or non-pathologic conditions angiogenesis oc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P9/00C12N15/02A61K48/00A61P19/02A61P27/00A61P27/02A61P27/06A61P35/00A61P35/02A61P35/04A61P37/00C07K16/18C07K16/28C07K19/00C12N5/10C12N5/20C12N15/13C12P21/08
CPCA61K48/00C07K2317/34C07K16/2896A61K2039/505A61P19/02A61P27/00A61P27/02A61P27/06A61P35/00A61P35/02A61P35/04A61P37/00A61P9/00
Inventor LIAO, FANGHICKLIN, DANIEL J.BOHLEN, PETER
Owner IMCLONE SYSTEMS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap